Strategic Early-Phase & PK Clinical Trial Execution
Celerion’s Global Clinical Development (GCD) team provides full-service CRO support for early-phase multi-site clinical studies conducted external to our clinical pharmacology units (CPUs). Specialized in complex renal and hepatic impairment pharmacokinetic (PK) studies, our strategic approach seamlessly integrates patient arms into a single Phase I protocol. This enables a rapid, streamlined transition from first-in-patient trials through clinical Proof-of-Concept (PoC) and Phase IIa studies. By leveraging our global site network, dedicated clinical monitoring, and rigorous compliance standards, we accelerate data delivery while ensuring total data integrity.





